$TSHA
Taysha Gene Therapies, Inc.

2022 Q1 Form 10-Q Financial Statement

#000156459022020260 Filed on May 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.47M $8.240M
YoY Change 39.19%
% of Gross Profit
Research & Development $1.250M $5.500M
YoY Change -77.27% 83.33%
% of Gross Profit
Depreciation & Amortization $300.0K $32.00K
YoY Change 837.5%
% of Gross Profit
Operating Expenses $1.250M $32.09M
YoY Change -96.1% 474.68%
Operating Profit -$49.65M -$32.09M
YoY Change 54.72% 474.68%
Interest Expense $849.0K $66.00K
YoY Change 1186.36% 144.44%
% of Operating Profit
Other Income/Expense, Net -$843.0K $66.00K
YoY Change -1377.27% -56.86%
Pretax Income -$50.11M -$32.02M
YoY Change 56.5%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$50.11M -$32.02M
YoY Change 56.48% 489.65%
Net Earnings / Revenue
Basic Earnings Per Share -$1.32
Diluted Earnings Per Share -$1.313M -$865.6K
COMMON SHARES
Basic Shares Outstanding 38.17M 37.76M
Diluted Shares Outstanding 38.17M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $96.63M $228.7M
YoY Change -57.75%
Cash & Equivalents $96.60M $228.7M
Short-Term Investments
Other Short-Term Assets $941.0K $839.0K
YoY Change 12.16%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $106.9M $239.6M
YoY Change -55.39%
LONG-TERM ASSETS
Property, Plant & Equipment $55.12M $2.500M
YoY Change 2104.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.965M $700.0K
YoY Change 466.43%
Total Long-Term Assets $59.09M $3.200M
YoY Change 1746.41%
TOTAL ASSETS
Total Short-Term Assets $106.9M $239.6M
Total Long-Term Assets $59.09M $3.200M
Total Assets $166.0M $242.8M
YoY Change -31.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $22.00M $4.100M
YoY Change 436.51%
Accrued Expenses $26.62M $14.90M
YoY Change 78.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $48.62M $19.00M
YoY Change 155.88%
LONG-TERM LIABILITIES
Long-Term Debt $37.39M $0.00
YoY Change
Other Long-Term Liabilities $29.25M $1.000M
YoY Change 2824.8%
Total Long-Term Liabilities $66.63M $1.000M
YoY Change 6563.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $48.62M $19.00M
Total Long-Term Liabilities $66.63M $1.000M
Total Liabilities $115.3M $20.00M
YoY Change 476.26%
SHAREHOLDERS EQUITY
Retained Earnings -$285.8M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $50.73M $222.9M
YoY Change
Total Liabilities & Shareholders Equity $166.0M $242.8M
YoY Change -31.64%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$50.11M -$32.02M
YoY Change 56.48% 489.65%
Depreciation, Depletion And Amortization $300.0K $32.00K
YoY Change 837.5%
Cash From Operating Activities -$40.80M -$22.04M
YoY Change 85.18% 1196.94%
INVESTING ACTIVITIES
Capital Expenditures $8.427M $534.0K
YoY Change 1478.09%
Acquisitions
YoY Change
Other Investing Activities -$3.000M
YoY Change
Cash From Investing Activities -$11.43M -$534.0K
YoY Change 2039.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -242.0K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -40.80M -22.04M
Cash From Investing Activities -11.43M -534.0K
Cash From Financing Activities -242.0K 0.000
Net Change In Cash -52.47M -22.57M
YoY Change 132.5% -238.22%
FREE CASH FLOW
Cash From Operating Activities -$40.80M -$22.04M
Capital Expenditures $8.427M $534.0K
Free Cash Flow -$49.23M -$22.57M
YoY Change 118.14% 1228.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
1250000
CY2021Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
5500000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
14000
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
66000
CY2022Q1 us-gaap Interest Expense
InterestExpense
849000
CY2022Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
8000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-843000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
66000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-50111000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-32024000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.31
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.87
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38174717
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36992377
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
95383000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5453000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-50111000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
50725000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-32024000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
222872000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-50111000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-32024000
CY2022Q1 us-gaap Depreciation
Depreciation
257000
CY2021Q1 us-gaap Depreciation
Depreciation
32000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5329000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
21000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3594000
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-194000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-271000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4184000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2544000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1872000
CY2022Q1 tsha Increase Decrease In Accrued Expense And Other Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherLiabilities
-538000
CY2021Q1 tsha Increase Decrease In Accrued Expense And Other Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherLiabilities
3183000
CY2021Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-8000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40804000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22035000
CY2022Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
3000000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8427000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
534000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11427000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-534000
CY2022Q1 tsha Payment Of Shelf Registration Costs
PaymentOfShelfRegistrationCosts
151000
CY2022Q1 tsha Employee Stock Purchase Plan Contributions
EmployeeStockPurchasePlanContributions
277000
CY2022Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-368000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-242000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-52473000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22569000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
151740000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
251253000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
99267000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
228684000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
96630000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228684000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
2637000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
99267000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
228684000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
419000
CY2022Q1 tsha Property And Equipment In Accounts Payable And Accrued Expenses
PropertyAndEquipmentInAccountsPayableAndAccruedExpenses
4513000
CY2021Q1 tsha Property And Equipment In Accounts Payable And Accrued Expenses
PropertyAndEquipmentInAccountsPayableAndAccruedExpenses
1101000
CY2021Q1 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
607000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
128000
CY2022Q1 tsha Research And Development License Not Yet Paid
ResearchAndDevelopmentLicenseNotYetPaid
1250000
CY2021Q1 tsha Research And Development License Not Yet Paid
ResearchAndDevelopmentLicenseNotYetPaid
5500000
CY2022Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2020-02-13
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-285800000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
96600000
CY2022Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.35
CY2021Q4 tsha Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
5218000
CY2022Q1 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
2705000
CY2021Q4 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
3298000
CY2022Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
566000
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
545000
CY2022Q1 tsha Prepaid Bonus
PrepaidBonus
136000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates and assumptions in the Company’s financial statements relate to the determination of the fair value of the common stock prior to the Company’s initial public offering (“IPO”) in September 2020 (as an input into stock-based compensation), and estimating preclinical manufacturing accruals and accrued or prepaid research and development expenses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. In response to the ongoing and rapidly evolving COVID-19 pandemic, management considered the impact of the estimated economic implications on the Company’s critical and significant accounting estimates, including assessment of impairment of long-lived assets.</p>
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1586000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1491000
CY2022Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
26620000
CY2022Q1 tsha Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
5793000
CY2021Q4 tsha Prepaid Bonus
PrepaidBonus
427000
CY2022Q1 us-gaap Prepaid Insurance
PrepaidInsurance
120000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
148000
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
941000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
863000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10261000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10499000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
29983000
CY2021Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0700
CY2021Q3 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2026-08-01
CY2021Q3 tsha Percentage Of Prepayment Of Facility
PercentageOfPrepaymentOfFacility
0.075
CY2022Q1 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
3000000.0
CY2021Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2021Q3 tsha Percentage Of Annual Default Interest Rate
PercentageOfAnnualDefaultInterestRate
0.05
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
55874000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
51109000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
754000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
499000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
55120000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50610000
CY2022Q1 us-gaap Depreciation
Depreciation
300000
CY2022Q1 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
15080000
CY2021Q4 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
11895000
CY2022Q1 tsha Accrued Severance
AccruedSeverance
2273000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2182000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7703000
CY2022Q1 tsha Accrued License Fees Current
AccruedLicenseFeesCurrent
1750000
CY2021Q4 tsha Accrued License Fees Current
AccruedLicenseFeesCurrent
3500000
CY2022Q1 tsha Accrued Property Plant And Equipment Current
AccruedPropertyPlantAndEquipmentCurrent
1501000
CY2021Q4 tsha Accrued Property Plant And Equipment Current
AccruedPropertyPlantAndEquipmentCurrent
2644000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1281000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1091000
CY2022Q1 tsha Accrued Clinical Trial Current
AccruedClinicalTrialCurrent
967000
CY2021Q4 tsha Accrued Clinical Trial Current
AccruedClinicalTrialCurrent
1659000
CY2022Q1 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
900000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
6667000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
20000000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
13333000
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
40000000
CY2022Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2614000
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
37386000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
0.85
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
0.15
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
1800
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5329000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3594000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-50111000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32024000
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38174717
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36992377
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.31
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.87
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7602457
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5905253
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2022Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
400000

Files In Submission

Name View Source Status
0001564590-22-020260-index-headers.html Edgar Link pending
0001564590-22-020260-index.html Edgar Link pending
0001564590-22-020260.txt Edgar Link pending
0001564590-22-020260-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gqxupkufbvrp000001.jpg Edgar Link pending
gqxupkufbvrp000002.jpg Edgar Link pending
gqxupkufbvrp000003.jpg Edgar Link pending
gqxupkufbvrp000004.jpg Edgar Link pending
gqxupkufbvrp000005.jpg Edgar Link pending
gqxupkufbvrp000006.jpg Edgar Link pending
gqxupkufbvrp000007.jpg Edgar Link pending
gqxupkufbvrp000008.jpg Edgar Link pending
gqxupkufbvrp000009.jpg Edgar Link pending
gqxupkufbvrp000010.jpg Edgar Link pending
gqxupkufbvrp000011.jpg Edgar Link pending
gqxupkufbvrp000012.jpg Edgar Link pending
gqxupkufbvrp000013.jpg Edgar Link pending
gqxupkufbvrp000014.jpg Edgar Link pending
gqxupkufbvrp000015.jpg Edgar Link pending
gqxupkufbvrp000016.jpg Edgar Link pending
gqxupkufbvrp000017.jpg Edgar Link pending
gqxupkufbvrp000018.jpg Edgar Link pending
gqxupkufbvrp000019.jpg Edgar Link pending
gqxupkufbvrp000020.jpg Edgar Link pending
gqxupkufbvrp000021.jpg Edgar Link pending
gqxupkufbvrp000022.jpg Edgar Link pending
gqxupkufbvrp000023.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tsha-10q_20220331.htm Edgar Link pending
tsha-10q_20220331_htm.xml Edgar Link completed
tsha-20220331.xsd Edgar Link pending
tsha-20220331_cal.xml Edgar Link unprocessable
tsha-20220331_def.xml Edgar Link unprocessable
tsha-20220331_lab.xml Edgar Link unprocessable
tsha-20220331_pre.xml Edgar Link unprocessable
tsha-ex311_6.htm Edgar Link pending
tsha-ex312_8.htm Edgar Link pending
tsha-ex321_7.htm Edgar Link pending
tsha-ex322_9.htm Edgar Link pending